Altered Ethanolamine Plasmalogen and Phosphatidylethano-lamine Concentrations in Serum of Patients with Bipolar Disorder (P08-117-19)

• Published in: Current developments in nutrition Vol. 3; no. Supplement_1; p. nzz044.P08-117-19
• Main Authors: Ogawa, Shintaro, Hattori, Kotaro, Goodenowe, Dayan, Kunugi, Hiroshi
• Format: Journal Article
• Language: English
• Published: Oxford Elsevier Inc 01.06.2019; Oxford University Press
• Subjects: Bipolar disorder; Energy and Macronutrient Metabolism
• ISSN: 2475-2991; 2475-2991
• DOI: 10.1093/cdn/nzz044.P08-117-19

Growing evidence has suggested that metabolic alterations of plasmalogen ethanolamine (PlsEtn) are implicated in neuropsychiatric diseases. However, few studies examined the association of peripheral blood PlsEtn levels with bipolar disorder (BP). In this study, we measured serum PlsEtn and phosphatidylethanolamine (PtdEtn) levels in patients with BP and healthy controls. We investigated the relationships between serum PlsEtn and PtdEtn levels, diagnosis, symptom severity and medication status. Subjects were 40 patients with BP (DSM-IV) and 40 healthy controls matched for age, sex, and ethnicity (Japanese). Informed consent was obtained from each subject. Serum levels of PlsEtn and PtdEtn were determined by liquid chromatography/tandem mass spectrometry. Serum PlsEtn were significantly lower in patients with BP compared with controls (P = 0.017). Serum PtdEtn levels were significantly lower in patients with a BP type I (n = 12) versus patients with BP type II (n = 24) diagnosis (P = 0.011). In the BP patients, symptom severity did not correlate with serum PlsEtn or PtdEtn levels. Low serum PlsEtn might be involved in the pathophysiology of BP. PtdEtn might be related differently with BP I and BP II. This study was supported by an Intramural Research Grant for Neurological and Psychiatric Disorders by the National Center of Neurology and Psychiatry (H.K.).